Literature DB >> 1481919

Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia.

A J Brady1, P A Poole-Wilson, S E Harding, J B Warren.   

Abstract

We investigated whether increased nitric oxide (NO) synthase activity within cardiac myocytes contributes to the depressed cardiac contractility observed in endotoxic shock. Isolated ventricular myocytes were studied to examine the effects of substrates and inhibitors of NO synthase on myocyte contractility. When stimulated electrically, the resting length of myocytes from control animals shortened by 5.3 +/- 0.3% (means +/- SE, n = 32). Baseline contraction of myocytes from endotoxin-treated animals was reduced to 3.0 +/- 0.3% (n = 17, P < 0.001). The NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 10(-4) M) had no effect on myocytes from control animals, but it increased the contraction of myocytes from endotoxin-treated animals by 40% (fractional shortening increased to 4.3 +/- 0.4%, P < 0.01). Similar results were obtained with NG-methyl-L-arginine. The effect of L-NAME could be reversed by excess L-arginine, but not D-arginine. The effect of endotoxin was abolished by dexamethasone pretreatment. Methylene blue also reversed the effects of endotoxin but had toxic effects on myocytes. Agents that either prevent synthesis or the effects of NO reverse the depression of myocyte contraction seen following endotoxin treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1481919     DOI: 10.1152/ajpheart.1992.263.6.H1963

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  44 in total

1.  Minocycline reverses IL-17A/TRAF3IP2-mediated p38 MAPK/NF-κB/iNOS/NO-dependent cardiomyocyte contractile depression and death.

Authors:  Tadashi Yoshida; Nitin A Das; Andrea J Carpenter; Reza Izadpanah; Senthil A Kumar; Sandeep Gautam; Shawn B Bender; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  Cell Signal       Date:  2020-06-15       Impact factor: 4.315

Review 2.  Endothelial modification of pulmonary vascular tone.

Authors:  N P Curzen; K B Jourdan; J A Mitchell
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

Review 3.  The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18-20 March 1995.

Authors:  M P Fink; D Payen
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

4.  Inducible nitric oxide synthase in the cardiovascular system.

Authors:  K Bhagat; P Vallance
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

Review 5.  Cardiac dysfunction in sepsis: new theories and clinical implications.

Authors:  R M Grocott-Mason; A M Shah
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

6.  Alterations in inotropy, nitric oxide and cyclic GMP synthesis, protein phosphorylation and ADP-ribosylation in the endotoxin-treated rat myocardium and cardiomyocytes.

Authors:  P V Sulakhe; L Sandirasegarane; J P Davis; X T Vo; W J Costain; R R Mainra
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

Review 7.  Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.

Authors:  A P Bolger; S D Anker
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

8.  Nitric oxide inhibits creatine kinase and regulates rat heart contractile reserve.

Authors:  W L Gross; M I Bak; J S Ingwall; M A Arstall; T W Smith; J L Balligand; R A Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

9.  Altered responsiveness to endothelin-1 of myocardium from pacing-induced heart failure model in the dog.

Authors:  K Li; J L Rouleau
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

10.  Role of controlled cardiac reoxygenation in reducing nitric oxide production and cardiac oxidant damage in cyanotic infantile hearts.

Authors:  K Morita; K Ihnken; G D Buckberg; M P Sherman; H H Young; L J Ignarro
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.